FindTrial
Sign In

YM155

DRUG10 trials

Sponsors

Astellas Pharma Inc, National Cancer Institute (NCI)

Conditions

Breast CancerCancerCancer of LungCancer of ProstateCancer of the LungCancer of the ProstateCarcinoma, Non-Small Cell LungLung Cancer

Phase 1

A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer
CompletedNCT01023386
Astellas Pharma IncCancer
Start: 2009-11-30End: 2010-03-31Updated: 2010-04-13
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
CompletedNCT01100931
National Cancer Institute (NCI)NSCLC, Solid Tumors
Start: 2010-02-28End: 2012-12-31Updated: 2015-10-19

Phase 2

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
CompletedNCT00257478
Astellas Pharma IncCancer of Prostate, Cancer of the Prostate, Prostate Cancer +1
End: 2007-03-31Updated: 2012-06-07
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
CompletedNCT00281541
Astellas Pharma IncMelanoma
Start: 2005-11-30End: 2007-06-30Target: 29Updated: 2012-06-07
LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy
CompletedNCT00328588
Astellas Pharma IncCancer of Lung, Cancer of the Lung, Carcinoma, Non-Small Cell Lung +2
Start: 2006-12-31End: 2007-03-31Updated: 2008-01-02
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
TerminatedNCT00498914
Astellas Pharma IncLymphoma, B-Cell Refractory, Lymphoma, Large-Cell, Diffuse
Start: 2007-06-30End: 2009-04-30Updated: 2015-09-04
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
CompletedNCT00818480
Astellas Pharma IncMelanoma, Non-Hodgkin's Lymphoma, Prostate Cancer
Start: 2006-02-28End: 2012-08-31Updated: 2015-09-04
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
CompletedNCT01007292
Astellas Pharma IncNon-Hodgkin's Lymphoma
Start: 2009-11-30End: 2015-06-30Updated: 2015-10-19
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
CompletedNCT01009775
Astellas Pharma IncMelanoma
Start: 2009-11-30End: 2012-08-31Updated: 2015-09-04
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
CompletedNCT01038804
Astellas Pharma IncBreast Cancer
Start: 2009-12-31End: 2013-06-30Updated: 2013-09-18

Related Papers

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
2013-07-14130 citations